OBJECTIVE This study aimed to investigate the correlation of A-kinase interacting protein 1 (AKIP1) with chemokine (C-X-C motif) ligand 1 (CXCL1) and CXCL2, as well as their associations with clinical characteristics and prognosis in prostate cancer patients. METHODS A total of 248 eligible prostate cancer patients who underwent surgery were consecutively recruited, and tumor tissues were collected during the surgery. AKIP1, CXCL1, and CXCL2 expression in tumor tissues were assessed by immunohistochemistry. Disease-free survival and overall survival were recorded, and the median follow-up time was 27 months. RESULTS The proportion of patients with AKIP1, CXCL1, and CXCL2 high expression was 56.5%, 63.7%, and 56.9%, respectively. Additionally, AKIP1 expression positively correlated with CXCL1 expression (P<0.001) and CXCL2 expression (P<0.001), and CXCL1 expression was positively associated with CXCL2 expression (P<0.001). Furthermore, AKIP1 expression positively correlated with pathological T stage (P<0.001) and pathological N stage (P=0.003). CXCL1 expression was positively associated with pathological T stage (P<0.001) and pathological N stage (P<0.001) as well. However, the CXCL2 expression only positively correlated with pathological T stage (P=0.002). Also, AKIP1 high expression correlated with worse disease-free survival (P=0.049) and OS (P=0.013), and CXCL1 high expression was associated with unfavorable disease-free survival (P=0.023) but not overall survival (P=0.052). CXCL2 expression was not correlated with disease-free survival (P=0.083) or overall survival (P=0.065). Multivariate Cox's regression disclosed that AKIP1 high expression independently predicted worse overall survival (P=0.009). CONCLUSION AKIP1 positively associates with CXCL1/2 and is a potential biomarker for disease monitoring as well as prognosis in prostate cancer.

中文翻译：

---

A-激酶相互作用蛋白 1，一种与前列腺癌晚期肿瘤特征和 CXCL1/2 相关的潜在生物标志物。

目的 本研究旨在探讨 A 激酶相互作用蛋白 1 (AKIP1) 与趋化因子 (CXC 基序) 配体 1 (CXCL1) 和 CXCL2 的相关性，以及它们与前列腺癌患者临床特征和预后的关系。方法连续招募符合条件的接受手术的前列腺癌患者248例，术中采集肿瘤组织。通过免疫组织化学评估肿瘤组织中 AKIP1、CXCL1 和 CXCL2 的表达。记录无病生存期和总生存期，中位随访时间为27个月。结果AKIP1、CXCL1、CXCL2高表达的患者比例分别为56.5%、63.7%、56.9%。此外，AKIP1 表达与 CXCL1 表达（P<0.001）和 CXCL2 表达（P<0. 001），CXCL1表达与CXCL2表达呈正相关（P<0.001）。此外，AKIP1的表达与病理T分期（P<0.001）和病理N分期（P=0.003）呈正相关。CXCL1表达与病理T分期（P<0.001）和病理N分期（P<0.001）呈正相关。然而，CXCL2表达仅与病理T分期呈正相关（P=0.002）。此外，AKIP1 高表达与较差的无病生存期（P=0.049）和 OS（P=0.013）相关，CXCL1 高表达与不利的无病生存期（P=0.023）相关，但与总生存期无关（P=0.052） ）。CXCL2 表达与无病生存期（P=0.083）或总生存期（P=0.065）无关。多元考克斯' s 回归揭示 AKIP1 高表达独立预测较差的总体生存率 (P=0.009)。结论 AKIP1 与 CXCL1/2 呈正相关，是前列腺癌疾病监测和预后的潜在生物标志物。